- Home
- CNCK vs AUPH Comparison
CNCK vs AUPH Comparison
Compare CNCK & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNCK
- AUPH
- Stock Information
- Founded
- CNCK 2012
- AUPH 1993
- Country
- CNCK Netherlands
- AUPH Canada
- Employees
- CNCK N/A
- AUPH N/A
- Industry
- CNCK
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- CNCK
- AUPH Health Care
- Exchange
- CNCK NYSE
- AUPH Nasdaq
- Market Cap
- CNCK 1.3B
- AUPH 1.1B
- IPO Year
- CNCK N/A
- AUPH 1999
- Fundamental
- Price
- CNCK $6.32
- AUPH $7.93
- Analyst Decision
- CNCK Buy
- AUPH Strong Buy
- Analyst Count
- CNCK 1
- AUPH 3
- Target Price
- CNCK $10.00
- AUPH $10.33
- AVG Volume (30 Days)
- CNCK 54.1K
- AUPH 989.8K
- Earning Date
- CNCK 02-12-2025
- AUPH 02-27-2025
- Dividend Yield
- CNCK N/A
- AUPH N/A
- EPS Growth
- CNCK N/A
- AUPH N/A
- EPS
- CNCK N/A
- AUPH N/A
- Revenue
- CNCK $2,354,350,618.00
- AUPH $220,361,000.00
- Revenue This Year
- CNCK N/A
- AUPH $36.97
- Revenue Next Year
- CNCK N/A
- AUPH $16.43
- P/E Ratio
- CNCK N/A
- AUPH N/A
- Revenue Growth
- CNCK 57.02
- AUPH 38.72
- 52 Week Low
- CNCK $6.32
- AUPH $4.71
- 52 Week High
- CNCK $14.99
- AUPH $10.67
- Technical
- Relative Strength Index (RSI)
- CNCK N/A
- AUPH 47.47
- Support Level
- CNCK N/A
- AUPH $7.50
- Resistance Level
- CNCK N/A
- AUPH $8.12
- Average True Range (ATR)
- CNCK 0.00
- AUPH 0.27
- MACD
- CNCK 0.00
- AUPH 0.02
- Stochastic Oscillator
- CNCK 0.00
- AUPH 53.49
About CNCK COINCHECK GROUP NV
Coincheck Group NV is a digital asset trading service company. It operates multi-cryptocurrency marketplaces and crypto asset exchanges in Japan and marketplace and exchange platforms on which diverse cryptocurrencies, including Bitcoin and Ethereum, are held and exchanged, and offers other retail-focused crypto services. It is also increasing user's access to digital products and solutions beyond cryptocurrencies, such as non-fungible tokens (NFTs). The company manages its business in one operating and reportable segment: Crypto Asset.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company. It provides products for patients suffering from serious diseases with a high unmet medical need. The firm is developing LUPKYNIS (voclosporin), an investigational drug, for the treatment of lupus nephritis (LN), and others. Geographically, it derives maximum revenue from the United States.